Print Friendly, PDF & Email

Supply Delays for CSL Behring’s Mononine®

October 26, 2018
Supply Delays for CSL Behring’s Mononine®

The National Hemophilia Foundation has learned that CSL Behring is experiencing intermittent supply delays of Mononine®, the company’s human plasma derived factor IX product for treatment of patients with hemophilia B. 

CSL is encouraging patients to contact their pharmacy regarding their individual prescription and, if necessary, contact their physician about their treatment plan. The company also acknowledges the concern and hardships this presents for patients, physicians and pharmacists, and will keep the community apprised of the situation so that therapy management decisions can be made from an informed position.